Tremfya-Pso/PsA mode of Action

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Tremfya® is the first biologic indicated for the management of PsA, fully human monoclonal antibody (mAb) that selectively targets IL‑231-3